title: [The primary mediastinal lymphoma: state of the art and therapeutical perspectives].
abstract: Within diffuse large B-cell lymphomas, the Primary Mediastinal Large B-Cell Lymphoma has to be considered as a separate and well-defined clinico-pathological entity. Its tendency to target young adults makes its social impact particularly significant; hence, the General Practitioner carries the responsibility for an early diagnosis. On the contrary, the extreme complexity of the available therapies makes a quick referral to specialized Clinical Centres of outmost importance, since this remains the best way to enrol as many patients as possible in therapeutic protocols. Nowadays, good clinical results and a favourable outcome are achievable, but some questions remain open. The role of radiotherapy still has to be clarified, both as a complete remission consolidation, as well as a treatment of the residual disease. Conversely, a golden standard for the second line treatment has not been clearly established.
authors.affiliation: Unità Dipartmentale Linformi, Diartmentato di Onco-Ematologia, IRCCS Ospedale San Raffaele, Milano. foppoli.marco@hsy.it
authors.forename: Marco
authors.initials: M
authors.lastname: Foppoli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Citterio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Donadoni
authors.forename: Silvia
authors.initials: S
authors.lastname: Govi
authors.forename: Andrés Jm
authors.initials: AJ
authors.lastname: Ferreri
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D059248:Chemoradiotherapy; D002637:Chest Pain / Q000209:etiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003952:Diagnostic Imaging; D004317:Doxorubicin / Q000008:administration & dosage; D004417:Dyspnea / Q000209:etiology; D042241:Early Diagnosis; D006801:Humans; D016130:Immunophenotyping; D002955:Leucovorin / Q000008:administration & dosage; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy / Q000628:therapy*; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016879:Salvage Therapy; D063189:Symptom Assessment; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001761:Bleomycin; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate